Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury

Fibrosis of the lung constitutes a major clinical challenge and novel therapies are required to alleviate the associated morbidity and mortality. Investigating the antifibrotic efficacy of drugs that are already in clinical practice offers an efficient strategy to identify new therapies. The phospho...

Descripción completa

Detalles Bibliográficos
Autores principales: Sisson, Thomas H., Christensen, Paul J., Muraki, Yo, Dils, Anthony J., Chibucos, Lauren, Subbotina, Natalya, Tohyama, Kimio, Horowitz, Jeffrey C., Matsuo, Takanori, Bailie, Marc, Nikam, Sham, Hazama, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021279/
https://www.ncbi.nlm.nih.gov/pubmed/29952109
http://dx.doi.org/10.14814/phy2.13753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021279/
https://www.ncbi.nlm.nih.gov/pubmed/29952109
http://dx.doi.org/10.14814/phy2.13753

Ejemplares similares